Antibody-drug Conjugate Information

General Information of This Antibody-drug Conjugate (ADC)

ADC ID	DRG0TFVTP
ADC Name	M9346A-SPP-DM1
Synonyms	M9346A SPP DM1 Click to Show/Hide
Organization	ImmunoGen, Inc.
Drug Status	Investigative
Indication	In total 2 Indication(s) Cervical cancer [ICD11:2C77] Investigative Ovarian cancer [ICD11:2C73] Investigative
Drug-to-Antibody Ratio	3.5-4
Structure
	3D MOL	2D MOL
Antibody Name	Mirvetuximab		Antibody Info
Antigen Name	Folate receptor alpha (FOLR1)		Antigen Info
Payload Name	Mertansine DM1		Payload Info
Therapeutic Target	Microtubule (MT)		Target Info
Linker Name	N-succinimidyl 4-(2-pyridyldithio) pentanoate (SPP)		Linker Info
Conjugate Type	Random conjugation through nucleophilic lysines.
Combination Type	Mertansine

General Information of The Activity Data Related to This ADC

Discovered Using Cell Line-derived Xenograft Model

Click To Hide/Show 1 Activity Data Related to This Level

Standard Type	Value	Units	Cell Line	Disease Model
Tumor Growth Inhibition value (TGI)	≈ 90.98	%	OVCAR-3 cells	Ovarian serous adenocarcinoma

Full List of Activity Data of This Antibody-drug Conjugate

Discovered Using Cell Line-derived Xenograft Model

Click To Hide/Show 1 Activity Data Related to This Level

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 90.98% (Day 20)	Positive FOLR1 expression (FOLR1 +++/++)
Method Description	Conjugates of the exemplary anti-FOLR1 antibodies were tested using an established xenograft model of OVCAR-3 cells implanted subcutaneous into SCID mice. Mice were randomized by body weight into treatment groups and treated once post cell inoculation with 5 mg/kg of one of the conjugates listed above or with PBS only.
In Vivo Model	OVCAR-3 CDX model
In Vitro Model	Ovarian serous adenocarcinoma	OVCAR-3 cells		CVCL_0465

References

Ref 1	Folate receptor 1 antibodies and immunoconjugates and uses thereof; 2011-09-01.